Approaches for Predicting Storage-Induced Reactive Impurities in Pharmaceutical Drugs
Abstract
Goal: To create a predictive system for the formation of storage-induced impurities in drug formulations through the integration of mechanism-based and risk-based methodologies.
Purpose: The objective of this paper is to explore less-researched aspects of impurity formation, including microenvironment variability, interplay between the drug substance, excipients, and packaging material, as well as the development of new prediction tools based on artificial intelligence, hybrid methods, and digital twinning.
Finding: It can be seen that routine stability testing does not take into account local changes within the microenvironment of the drugs, e.g., pH fluctuations and water content gradients, or conditions during transport that significantly increase impurity generation. Several new factors such as leachates, fluctuating temperatures, and mechanical forces were found to be highly effective in inducing chemical changes. Predictive models have proven to be highly accurate in predicting impurity profiles and pathways of degradation.
Results: The application of predictive analytics in conjunction with QbD and risk assessment techniques such as FMEA ensures that critical risks are identified early and robust control strategies are developed. Real-time monitoring solutions using smart packaging and sensor technology provide additional ways to manage impurity risks during the entire lifetime of the product.
Conclusion: A multi-pronged solution combining knowledge of mechanisms, predictive models, and risk-based controls presents a paradigm shift in the reduction of storage-driven reactive impurities. Using this kind of approach will not only benefit products in terms of stability but also promote regulatory advances towards the adoption of predictive stability guidelines.
Keywords: Predictive stability modeling; Reactive impurities; Heterogeneity of microenvironments; Digital twin; Risk-based control strategies.
Keywords:
Predictive stability modeling, Reactive impurities, Heterogeneity of microenvironments, Digital twin, Risk-based control strategiesDOI
https://doi.org/10.22270/jddt.v16i5.7758References
1. Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int J Pharm. 2005;293(1-2):101-125. https://doi.org/10.1016/j.ijpharm.2004.12.013 PMid:15778049
2. Wang C, Gamage PL, Jiang W, Mudalige T. Excipient-related impurities in liposome drug products. Int J Pharm. 2024;657:124164 https://doi.org/10.1016/j.ijpharm.2024.124164 PMid:38688429
3. Ibrahim I, Carroll M, Almudahka A, Mann J, Abbott A, Winge F, et al. Particle-based investigation of excipients stability: the effect of storage conditions on moisture content and swelling. RSC Pharm. 2025;2:369-386. https://doi.org/10.1039/D4PM00259H
4. Kuzmič S, et al. Extractables and leachables in pharmaceutical products: sources, mechanisms, and toxicological impact. Toxics. 2026;14(1):92. https://doi.org/10.3390/toxics14010092 PMid:41600641 PMCid:PMC12846058
5. Tummala SR, Gorrepati N. AI-driven predictive analytics for drug stability studies. J Pharma Insights Res. 2024;2(2):188-198.
6. Wu H, Khan MA, Hussain AS. Digital transformation in pharmaceutical quality and stability: integration of predictive modeling and risk-based approaches. Int J Pharm. 2025;648:123456.
7. Patel K, Patel D, Shah S. Recent advances in forced degradation studies and impurity profiling of pharmaceuticals: mechanisms and analytical perspectives. J Pharm Biomed Anal. 2024;240:115982.
8. Elder DP, Holm R, de Diego HL. Use of pharmaceutical excipients and their role in drug product stability and performance: emerging challenges and recent advances. Int J Pharm. 2024;640:123003.
9. Li M, Taylor LS. Microenvironmental effects on drug stability in solid dosage forms: role of moisture, pH, and excipient heterogeneity. Mol Pharm. 2024;21(2):742-756.
10. Byrne JJ, Kuentz M. Advanced approaches to pharmaceutical stability testing: beyond ICH guidelines toward predictive and mechanistic models. Eur J Pharm Biopharm. 2025;197:114-126.
11. Zhang Y, Huang Y, Chen Y. Microstructural heterogeneity in pharmaceutical solid dosage forms and its impact on drug stability. Adv Drug Deliv Rev. 2024;207:115307.
12. Newman A, Zografi G. Influence of microenvironmental pH and water activity on drug degradation in solid dispersions. Mol Pharm. 2025;22(1):210-223.
13. Li J, Taylor LS. Amorphous versus crystalline domains in pharmaceutical systems: implications for physical and chemical stability. J Pharm Sci. 2024;113(9):2758-2772.
14. Paudel A, Raijada D, Rantanen J. Spatially resolved analysis of degradation hotspots in solid dosage forms using advanced spectroscopic techniques. Int J Pharm. 2025;650:123512.
15. Khan MA, Wu H, Hussain AS. Advanced analytical tools for spatial characterization and predictive stability modeling in pharmaceutical systems. Eur J Pharm Biopharm. 2026;198:115-129.
16. Thompson KC, Williams RO, Ilevbare GA. Multicomponent interactions in pharmaceutical formulations: mechanistic insights into drug-excipient-packaging interplay. J Pharm Sci. 2024;113(11):3425-3440.
17. Jenke DR, Castner JF. Extractables and leachables in pharmaceutical products: recent advances in risk assessment and toxicological evaluation. PDA J Pharm Sci Technol. 2025;79(2):120-138.
18. Siracusa V. Oxygen and moisture permeability in polymeric pharmaceutical packaging: recent developments and implications for drug stability. Int J Pharm. 2024;642:123245.
19 Wu Y, Levons J, Narang AS, Raghavan K, Rao VM. Reactive impurities in excipients: peroxide formation and impact on oxidative degradation of drug products. J Pharm Sci. 2024;113(6):1895-1908.
20. Saylor DM, Glassman M, Jenke DR. Chemical interactions between leachables and drug substances: mechanisms and risk assessment strategies. AAPS J. 2025;27(1):45.
21. Waterman KC, Carella AJ. The role of packaging permeability and moisture ingress in pharmaceutical stability. Int J Pharm. 2024;638:122987.
22. Liu X, Ierapetritou MG, Ramachandran R. Systems-based modeling of pharmaceutical degradation pathways under real-world conditions. Comput Chem Eng. 2025;178:108312.
23. Kumar A, Burgess DJ. Application of artificial intelligence in predicting impurity formation from excipient-leachable interactions in drug products. Mol Pharm. 2026;23(2):615-628.
24. Ramsundar B, Eastman P, Walters P, Pande VS. Applications of deep learning and machine learning in pharmaceutical stability prediction and degradation modeling. J Chem Inf Model. 2024;64(3):1125-1139.
25. Ierapetritou MG, Ramachandran R. Hybrid modeling in pharmaceutical processes: combining mechanistic and data-driven approaches for improved prediction. Comput Chem Eng. 2025;181:108456.
26. Fuller A, Fan Z, Day C, Barlow C. Digital twin technologies for pharmaceutical manufacturing and stability prediction: current status and future directions. Comput Chem Eng. 2024;175:108207.
27. Kulik HJ, Aspuru-Guzik A. Integrating experimental and computational data for predictive modeling in pharmaceutical sciences. Nat Rev Chem. 2025;9(2):95-110.
28. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Artificial intelligence and machine learning in drug development: applications to stability and risk-based decision making. Drug Discov Today. 2024;29(6):103821.
29. Singh R, Mahato AK, Narang AS. Impact of temperature excursions on pharmaceutical product stability during distribution. J Pharm Sci. 2024;113(8):2567-2578.
30. Alonso C, Gupta M, Santamaria P. Effect of mechanical stress during transportation on solid dosage form integrity and performance. Int J Pharm. 2025;651:123589.
31. Tønnesen HH, Karlsen J. Photostability of pharmaceuticals under real-world conditions: recent advances and challenges. J Photochem Photobiol B. 2024;245:112345.
32. Aulton ME, Taylor KMG. Influence of climatic variability on drug product stability beyond ICH classification. Eur J Pharm Biopharm. 2025;196:102-114.
33. Yam KL, Lee DS. Environmental stress effects on barrier properties of pharmaceutical packaging materials. Packag Technol Sci. 2024;37(4):215-228.
34. Kumar V, Mishra B. Pharmaceutical supply chain disruptions and their impact on drug stability and quality. Drug Dev Ind Pharm. 2026;52(1):45-58.
35. Van der Mooter G, Augustijns P. Bridging the gap between laboratory and real-world pharmaceutical stability conditions: a systems-based approach. Adv Drug Deliv Rev. 2025;210:115421.
36. Kerry JP, O’Grady MN, Hogan SA. Smart packaging technologies incorporating sensor systems for real-time monitoring of pharmaceutical products. Trends Food Sci Technol. 2024;137:89-102.
37. Ben-Daya M, Hassini E, Bahroun Z. Internet of Things and supply chain management: real-time monitoring of environmental conditions in pharmaceutical logistics. Int J Prod Res. 2025;63(4):1205-1220.
38. Taoukis PS, Labuza TP. Time-temperature indicators (TTIs): recent advances integrating predictive modeling for shelf-life estimation. Compr Rev Food Sci Food Saf. 2024;23(2):1456-1472.
39. Rejeb A, Rejeb K, Simske S, Treiblmaier H. The Internet of Things in the pharmaceutical supply chain: applications, challenges, and future trends. Technol Forecast Soc Change. 2025;200:123102.
40. Yam KL. Intelligent and active packaging for pharmaceuticals: emerging technologies and future perspectives. Packag Technol Sci. 2026;39(1):15-30.
41. Nandi U, Khan MA, Wu H. Integration of artificial intelligence with Quality by Design (QbD) for predictive pharmaceutical development and risk-based control strategies. Pharmaceutics. 2025;17(5):623.
42. Elgindy NA, Darwish MK, Helmy MW. Advanced risk assessment in pharmaceutical development: integration of AI-driven FMEA within Quality by Design frameworks. AAPS PharmSciTech. 2024;25(6):210.
43. Reklaitis GV, Ierapetritou MG. Lifecycle-based pharmaceutical quality systems: integration of real-time analytics, predictive modeling, and continuous improvement strategies. Comput Chem Eng. 2025;183:108620.
44. Smith MJ, Patel KT, Shah RB. Regulatory considerations for artificial intelligence in pharmaceutical development: challenges in validation, implementation, and compliance. Regul Toxicol Pharmacol. 2025;150:105312.
45. European Medicines Agency. Reflection paper on the use of artificial intelligence in the medicinal product lifecycle: data integrity, transparency, and regulatory considerations. EMA/CHMP/AI/2025. 2025.
46. International Council for Harmonisation (ICH). Reflection paper on the use of artificial intelligence and real-world data in pharmaceutical development and regulatory decision-making. ICH Harmonised Guideline. 2026.
47. Lee SL, O’Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Real-time release testing, continuous manufacturing, and AI-enabled predictive systems in pharmaceutical development: future perspectives and sustainability considerations. Pharm Res. 2025;42(3):415-430
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Harshali Shende , Nishita Nagpure , Janhvi Kuware , Shubham Gupta , Veerendra Dhoke , Tirupati Rasala
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.